Publication | Closed Access

Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma

Medicinal ChemistryMedicineVegfr-2 InhibitorsPharmacologyAnti-cancer AgentDrug DevelopmentMolecular DockingRadiation OncologyTumor MicroenvironmentHepatocellular CarcinomaDrug Discovery